Adeno-associated virus (AAV) vectored products are currently leading candidates for gene therapy applications with multiple approved products and many more in clinical trials.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.
Researchers at Stanford have developed methods to overcome the limited packaging capacity of adeno-associated virus (AAV) vectors and enable their use in integration of large transgenes.
Stanford researchers have developed a method that can tune the ratio between reversible (RE) and irreversible (IRE) electroporation through waveform adjustments.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.